Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in anti-TNF-refractory active radiographic axial spondyloarthritis
RBR-3q2sdtPhase 3Recruiting
- Sponsor
- LMK Serviços Médicos
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ustekinumab in ankylosing spondylitis (AS) (3 arms), sponsored by LMK Serviços Médicos. Started Sep 2015; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on RBR-3q2sdt.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3q2sdt.